Next Article in Journal
Previous Article in Journal
Pharmaceuticals 2014, 7(6), 634-661; doi:10.3390/ph7060634
Review

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors

Received: 15 January 2014; in revised form: 8 May 2014 / Accepted: 12 May 2014 / Published: 26 May 2014
(This article belongs to the Special Issue HDAC Inhibitors 2014)
View Full-Text   |   Download PDF [401 KB, uploaded 26 May 2014]
Abstract: Histone deacetylases (HDACs) enzymes, which affect the acetylation status of histones and other important cellular proteins, have been recognized as potentially useful therapeutic targets for a broad range of human disorders. Emerging studies have demonstrated that different types of HDAC inhibitors show beneficial effects in various experimental models of neurological disorders. HDAC enzymes comprise a large family of proteins, with18 HDAC enzymes currently identified in humans. Hence, an important question for HDAC inhibitor therapeutics is which HDAC enzyme(s) is/are important for the amelioration of disease phenotypes, as it has become clear that individual HDAC enzymes play different biological roles in the brain. This review will discuss evidence supporting the involvement of HDAC1 and HDAC3 in polyglutamine disorders, including Huntington’s disease, and the use of HDAC1- and HDAC3-selective HDAC inhibitors as therapeutic intervention for these disorders. Further, while HDAC inhibitors are known alter chromatin structure resulting in changes in gene transcription, understanding the exact mechanisms responsible for the preclinical efficacy of these compounds remains a challenge. The potential chromatin-related and non-chromatin-related mechanisms of action of selective HDAC inhibitors will also be discussed.
Keywords: histone deacetylase (HDAC); HDAC1; HDAC3; subtype; selective; neurodegenerative; polyglutamine; histone; chromatin; mechanism histone deacetylase (HDAC); HDAC1; HDAC3; subtype; selective; neurodegenerative; polyglutamine; histone; chromatin; mechanism
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Thomas, E.A. Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors. Pharmaceuticals 2014, 7, 634-661.

AMA Style

Thomas EA. Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors. Pharmaceuticals. 2014; 7(6):634-661.

Chicago/Turabian Style

Thomas, Elizabeth A. 2014. "Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors." Pharmaceuticals 7, no. 6: 634-661.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert